Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Fineline Cube Jul 16, 2026
Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Fineline Cube Jul 16, 2026
Company Drug

Simcere’s Cosela Receives First Prescription in China for CDK4/6 Inhibition

Fineline Cube Jan 29, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the issuance of the first prescription for...

Policy / Regulatory

China Updates Export Controls on Technologies, Adds Gene Editing to List

Fineline Cube Jan 29, 2023

The Ministry of Finance (MOF) has released an updated notification regarding technologies banned and restricted...

Company Drug

Novartis’ Kisqali Receives NMPA Approval for Premenopausal Breast Cancer

Fineline Cube Jan 28, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving marketing approval from the National Medical...

Company Drug

Fosun Pharma’s Comirnaty Bivalent Vaccine Approved in Macau for Booster Shots

Fineline Cube Jan 28, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its Comirnaty...

Company Drug

HuidaGene Receives FDA IND Approval for Ophthalmology Gene Therapy HG004

Fineline Cube Jan 28, 2023

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving Investigational New Drug (IND) approval from...

Company Deals

Yinghe Brain Science Raises RMB 100 Million in Angel Financing Round

Fineline Cube Jan 28, 2023

Shenzhen Yinghe Brain Science Co., Ltd, a China-based neurotechnology firm, has reportedly raised over RMB...

Company Deals

HutchMed Signs Licensing Deal with Takeda for Global Fruquintinib Development

Fineline Cube Jan 28, 2023

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced a licensing deal with Japanese...

Company Deals

Tianjin-Based Protein T Raises RMB 100 Million in Series A Financing

Fineline Cube Jan 28, 2023

Tianjin-based biotech Protein T, focused on multi-omics research, has reportedly raised close to RMB 100...

Company Drug

Ascletis Receives IND Approval for ASC10 in Monkeypox Treatment

Fineline Cube Jan 28, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving Investigational New Drug (IND) approval from...

Company Drug

Legend Biotech’s Carvykti Meets Primary Endpoint in CARTITUDE-4 Phase III Study

Fineline Cube Jan 28, 2023

Legend Biotech (NASDAQ: LEGN) has released positive data from the CARTITUDE-4 Phase III study, evaluating...

Company Drug

CSPC’s Octreotide Long-Acting Injection Approved for Acromegaly Clinical Study

Fineline Cube Jan 20, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...

Company Drug

BeiGene’s Brukinsa Approved by FDA for Chronic Lymphocytic Leukemia

Fineline Cube Jan 20, 2023

China-based BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that the US FDA has...

Company Deals

Dartsbio Pharmaceuticals Secures RMB 100 Million in Series B Financing

Fineline Cube Jan 20, 2023

Guangdong-based antibody drug developer Dartsbio Pharmaceuticals has reportedly raised over RMB 100 million in a...

Company Drug

CNBG-Virogin’s Omicron-Targeted mRNA Vaccine Approved for Clinical Trials

Fineline Cube Jan 20, 2023

CNBG-Virogin Biotech (Shanghai) Co., Ltd has announced obtaining clinical trial approval from the National Medical...

Company Drug

Hepagene’s FXR Agonist HPG1860 Shows Positive Phase IIa Data in NASH Study

Fineline Cube Jan 20, 2023

China-based liver disease specialist Hepagene Therapeutics (HK) Limited has revealed positive data from the Phase...

Company Deals

Ascentage Pharma Raises HKD 550 Million in Secondary Offering for Pipeline Expansion

Fineline Cube Jan 19, 2023

Suzhou-based Ascentage Pharma (HKG: 6855) is set to conduct a secondary offering of 22.5 million...

Company Drug

BMS’s Opdivo Approved in China for Neoadjuvant Therapy in Urothelial Carcinoma

Fineline Cube Jan 19, 2023

US-based Bristol-Myers Squibb (BMS, NYSE: BMY) has secured another new indication approval in China for...

Policy / Regulatory

NHSA Updates 2022 National Reimbursement Drug List with 2,967 Drug Varieties

Fineline Cube Jan 19, 2023

The National Healthcare Security Administration (NHSA) has revealed the results of the 2022 National Reimbursement...

Company Drug

Harbour BioMed Receives FDA Approval for HBM1007 Clinical Study

Fineline Cube Jan 19, 2023

China-based Harbour BioMed (HKG: 2142) has announced receiving approval from the US FDA to initiate...

Company Drug

Joincare’s Biosimilar Tocilizumab Approved for Marketing in China

Fineline Cube Jan 19, 2023

China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that its subsidiary Zhuhai...

Posts pagination

1 … 600 601 602 … 696

Recent updates

  • InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor
  • Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B
  • Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches
  • China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline
  • Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Company

Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.